Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early‑stage ovarian cancer according to imaging tumor subtypes

  • Authors:
    • Young‑Jae Lee
    • Yong‑Man Kim
    • Ji‑Sik Kang
    • So‑Hyun Nam
    • Dae‑Yeon Kim
    • Young‑Tak Kim
  • View Affiliations

  • Published online on: May 14, 2020     https://doi.org/10.3892/ol.2020.11629
  • Pages: 931-938
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to compare the accuracy of the Risk of Ovarian Malignancy Algorithm (ROMA) and cancer antigen (CA)125 to discriminate between benign ovarian tumors and early‑stage ovarian cancer according to imaging tumor subtypes associated with post‑operative histopathological findings. A total of 1,207 patients who were assessed using the ROMA test due to suspected early‑stage ovarian cancer and underwent surgery at Asan Medical Center (Seoul, Korea) between September 2014 and March 2018 were identified. A total of 981 patients who met the inclusion criteria were included in the retrospective analysis. Among the 981 subjects, 816 had benign tumors, 90 had malignant tumors and 75 had borderline tumors. Of the patients diagnosed with ovarian cancer or borderline tumor, 47.3% were judged as high‑risk by the ROMA test and 58.2% had CA125 levels of >35 U/ml. The specificity and accuracy of ROMA were higher compared with those of CA125 in pre‑menopausal females. However, the superiority of the ROMA test in the identification of malignant ovarian tumors compared with CA125 was only observed in patients with endometriotic‑type tumors but not in any of the other tumor subtypes. In the endometriotic type of ovarian tumor, the superiority of the ROMA test compared to CA125 was confirmed in triage of ovarian tumor. However, the sensitivity and specificity of ROMA and CA125 were similar for the other tumor types. Therefore, future development of better tumor‑specific biomarkers for triage of ovarian tumor is required.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Lee, Y., Kim, Y., Kang, J., Nam, S., Kim, D., & Kim, Y. (2020). Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early‑stage ovarian cancer according to imaging tumor subtypes. Oncology Letters, 20, 931-938. https://doi.org/10.3892/ol.2020.11629
MLA
Lee, Y., Kim, Y., Kang, J., Nam, S., Kim, D., Kim, Y."Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early‑stage ovarian cancer according to imaging tumor subtypes". Oncology Letters 20.1 (2020): 931-938.
Chicago
Lee, Y., Kim, Y., Kang, J., Nam, S., Kim, D., Kim, Y."Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early‑stage ovarian cancer according to imaging tumor subtypes". Oncology Letters 20, no. 1 (2020): 931-938. https://doi.org/10.3892/ol.2020.11629